Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Shares Outstanding (2020 - 2025)

Historic Shares Outstanding for SAB Biotherapeutics (SABSW) over the last 6 years, with Q3 2025 value amounting to $47.5 million.

  • SAB Biotherapeutics' Shares Outstanding rose 41216.04% to $47.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.5 million, marking a year-over-year increase of 41216.04%. This contributed to the annual value of $9.3 million for FY2024, which is 68.29% up from last year.
  • Latest data reveals that SAB Biotherapeutics reported Shares Outstanding of $47.5 million as of Q3 2025, which was up 41216.04% from $9.3 million recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Shares Outstanding registered a high of $47.5 million during Q3 2025, and its lowest value of $4.3 million during Q4 2021.
  • In the last 5 years, SAB Biotherapeutics' Shares Outstanding had a median value of $9.3 million in 2024 and averaged $18.2 million.
  • Its Shares Outstanding has fluctuated over the past 5 years, first crashed by 8828.95% in 2023, then soared by 41216.04% in 2025.
  • Over the past 5 years, SAB Biotherapeutics' Shares Outstanding (Quarter) stood at $4.3 million in 2021, then increased by 17.14% to $5.1 million in 2022, then surged by 82.18% to $9.3 million in 2023, then grew by 0.68% to $9.3 million in 2024, then soared by 408.89% to $47.5 million in 2025.
  • Its Shares Outstanding was $47.5 million in Q3 2025, compared to $9.3 million in Q2 2025 and $9.3 million in Q1 2025.